| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 05/26/2011 | US20110123596 Silica sol material having at least one therapeutically active substance for producing biologically degradable and/or resorbable silica gel materials for human medicine and/or medical technology |
| 05/26/2011 | US20110123595 Personal Stimulating Wiping Systems |
| 05/26/2011 | US20110123592 Biomaterials |
| 05/26/2011 | US20110123591 Tumoricidal, bactericidal, or viricidal macrophage activation |
| 05/26/2011 | US20110123590 Selective Expansion of Regulatory T Cells |
| 05/26/2011 | US20110123589 Three-dimensional nanocomposite materials consisting of a polysaccharidic matrix and metallic nanoparticles, preparation and use thereof |
| 05/26/2011 | US20110123588 Antimicrobial composites, films, labelstocks and labels |
| 05/26/2011 | US20110123586 Inhibition of quorum sensing-mediated processes in bacteria |
| 05/26/2011 | US20110123584 Temperature Change Compositions and Tissue Products Providing a Cooling Sensation |
| 05/26/2011 | US20110123581 Soft capsule |
| 05/26/2011 | US20110123577 Method Of Delivering Stable Topical Drug Compositions |
| 05/26/2011 | US20110123576 Intestinal environment-improving agent |
| 05/26/2011 | US20110123575 Modified release niacin formulations |
| 05/26/2011 | US20110123574 Inhalable sustained therapeutic formulations |
| 05/26/2011 | US20110123573 Methods and compositions for treating phenylketonuria |
| 05/26/2011 | US20110123572 Activated fibroblasts for treating tissue and/or organ damage |
| 05/26/2011 | US20110123566 Endogenous adjuvant molecules and uses thereof |
| 05/26/2011 | US20110123513 Alkaline phosphatase to reduce or prevent weight gain |
| 05/26/2011 | US20110123461 Compositions and Methods for the Maintenance of Oral Health |
| 05/26/2011 | US20110123459 Anaerobic Iodine Solution |
| 05/26/2011 | US20110123456 Hollow biodegradable nanospheres and nanoshells for delivery of therapeutic and/or imaging molecules |
| 05/26/2011 | US20110123453 Polyoxazolines with Inert Terminating Groups, Polyoxazolines Prepared from Protected Initiating Groups and Related Compounds |
| 05/26/2011 | US20110123451 Method for Cell Delivery Using Targeted Liposomes Associated with a Hemolysin |
| 05/26/2011 | US20110123448 Oil body carriers, uses in target therapy and/or detection of the same, and fusion proteins comprised therein |
| 05/26/2011 | US20110123446 Degradable compounds and methods of use thereof, particularly with particle replication in non-wetting templates |
| 05/26/2011 | US20110123438 Universal anchor peptide for nanoparticles |
| 05/26/2011 | DE102009047092A1 Verwendung eines triterpenhaltigen Oleogels zur Wundheilung Using a triterpenhaltigen oleogel for wound healing |
| 05/26/2011 | CA2781718A1 Process for the preparation of gadobenate dimeglumine complex in a solid form |
| 05/26/2011 | CA2781580A1 Topical foam composition |
| 05/26/2011 | CA2781579A1 Topical foam composition |
| 05/26/2011 | CA2781467A1 Formulations of antibody |
| 05/26/2011 | CA2781434A1 Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases |
| 05/26/2011 | CA2781329A1 Magnetic iron oxide fine particles, and magnetic particle-containing water dispersion and process for producing the same |
| 05/26/2011 | CA2781286A1 Oral formulation for dexlansoprazole |
| 05/26/2011 | CA2781139A1 Use of prostaglandins f2alpha and analogues for the healing of corneal and conjunctival lesions |
| 05/26/2011 | CA2781108A1 Drug-loaded fibers |
| 05/26/2011 | CA2781027A1 Method for treating retinal conditions using an intraocular tamponade |
| 05/26/2011 | CA2781012A1 Inhalation solutions |
| 05/26/2011 | CA2780756A1 Compositions and methods comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions |
| 05/26/2011 | CA2780586A1 Combination therapy for treating or preventing an inflammatory skin disorder |
| 05/26/2011 | CA2780554A1 Formulation for hgh and rhigf-1 combination |
| 05/26/2011 | CA2779490A1 Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity |
| 05/26/2011 | CA2778432A1 Parenteral formulations of gemcitabine derivatives |
| 05/26/2011 | CA2777842A1 Cooling substrates with hydrophilic containment layer and method of making |
| 05/25/2011 | EP2325205A2 Crystals of whole antibodies and fragments thereof and methods for making and using them |
| 05/25/2011 | EP2325193A2 Methods and compositions for therapeutic use of RNA interference |
| 05/25/2011 | EP2324861A1 In vivo use of water absorbent polymers |
| 05/25/2011 | EP2324854A1 Drug sustained release agent, adsorbent, functional food, mask, and adsorptive sheet |
| 05/25/2011 | EP2324850A1 Solid vaccine formulation |
| 05/25/2011 | EP2324833A1 Film preparation containing loperamide hydrochloride |
| 05/25/2011 | EP2324830A1 Process for the preparation of a monocyclic azole derivative that inhibits the interaction of ligands with rage |
| 05/25/2011 | EP2324826A1 Hydrophilic amino acid-containing preparation having improved taste |
| 05/25/2011 | EP2324822A2 Oral dosage forms for delivery of therapeutic agents comprising a mechnical fastener |
| 05/25/2011 | EP2324821A1 Oral care compositions |
| 05/25/2011 | EP2324820A1 Stable Fluindione composition comprising one or more antioxidant agents |
| 05/25/2011 | EP2324812A2 Composition exhibiting enhanced formulation stability and delivery of topical active ingredients |
| 05/25/2011 | EP2324362A1 Dye application for confocal imaging of cellular microstructure |
| 05/25/2011 | EP2324054A2 Phosphopeptides and use of the same |
| 05/25/2011 | EP2324045A2 Photo-crosslinked nucleic acid hydrogels |
| 05/25/2011 | EP2323725A2 An extracorporeal cell-based therapeutic device and delivery system |
| 05/25/2011 | EP2323673A1 Antimicrobial silver solutions |
| 05/25/2011 | EP2323636A1 Chelating amphiphilic polymers |
| 05/25/2011 | EP2323635A2 Fibrous surface structure containing active ingredients with controlled release of active ingredients, use thereof and method for the production thereof |
| 05/25/2011 | EP2323634A1 Ropinirole composition |
| 05/25/2011 | EP2323633A2 Stable pharmaceutical composition for optimized delivery of an hiv attachment inhibitor |
| 05/25/2011 | EP2323632A1 Retard tablets containing quetiapine |
| 05/25/2011 | EP2323631A1 Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion |
| 05/25/2011 | EP2323630A2 Methods, compositions and systems for local delivery of drugs |
| 05/25/2011 | EP2323629A1 Lyophilization above collapse |
| 05/25/2011 | EP2323628A2 Carrier nanoparticles and related compositions, methods and systems |
| 05/25/2011 | EP2323627A1 Novel rapid-effect pharmaceutical forms and uses of resulting pharmaceutical compositions |
| 05/25/2011 | EP2323626A2 Parenteral composition comprising microspheres with a diameter between 10 and 20 microns |
| 05/25/2011 | EP2323625A2 New composition for the treatment of ecchymotic pigmentations |
| 05/25/2011 | EP2323624A2 Modulation of toll-like receptor 8 expression by antisense oligonucleotides |
| 05/25/2011 | EP2323623A1 Pharmaceutical compositions |
| 05/25/2011 | EP2323622A1 Co-crystals and pharmaceutical formulations comprising the same |
| 05/25/2011 | EP2323613A2 Composite particles having an antioxidant-based protective system, and topical compositions comprising the same |
| 05/25/2011 | EP2323605A1 Transdermal delivery of oligosaccharides |
| 05/25/2011 | EP2252284B1 Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability |
| 05/25/2011 | EP2082750B1 Oral recombinant helicobacter pylori vaccine and preparing method thereof |
| 05/25/2011 | EP2066705B1 Cationic polymers as thickeners for aqueous and alcoholic compositions |
| 05/25/2011 | EP1973529B1 Disintegrating loadable tablets |
| 05/25/2011 | EP1827379B8 Formulations containing alkylphosphocholines using novel negative charge carriers |
| 05/25/2011 | EP1534296B1 Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| 05/25/2011 | EP1501771B1 Method of preparing porous calcium phosphate granules |
| 05/25/2011 | EP1482912B1 Naltrexone hydrochloride compositions |
| 05/25/2011 | EP1439847B1 Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract |
| 05/25/2011 | EP1294361B1 Compositions and methods to improve the oral absorption of antimicrobial agents |
| 05/25/2011 | EP0947584B1 Loxoprofen-containing preparation for external use |
| 05/25/2011 | CN201840679U External bacteriostatic tablet for gynaecology |
| 05/25/2011 | CN201840678U Microecological vagina stype |
| 05/25/2011 | CN201840677U Preparation structure with carbon film layer |
| 05/25/2011 | CN1966036B Chinese medicine for treating gastrointestinal disease and preparation method thereof |
| 05/25/2011 | CN1942177B Bazedoxifene acetate solid dispersion formulations |
| 05/25/2011 | CN1913872B Pre-metered dry powder inhaler for moisture-sensitive medicaments |
| 05/25/2011 | CN1816538B Preventive or therapeutic composition for viral infectious disease |
| 05/25/2011 | CN1813886B Chinese medicine formulation for activating blood flow and removing blood stasis and stopping pain, and its preparing method |
| 05/25/2011 | CN1813872B Liver-reinforcing and toxin-dispelling capsule for treating heptitis B and its preparing process |
| 05/25/2011 | CN1785180B Method for detecting compound bismuth potassium citrate metronidazole |
| 05/25/2011 | CN1660278B Compound injection of Chinese angelica root and chuanxiong rhizome and preparation method |